Skip to Content
image description
  • image description
  • image description
  • image description

Cancer Clinical Trials

Breast - Advanced ER (+) HER2 (-)

Monarch 3 (I3Y-MC-JPBM)

A randomized, double-blind, placebo-controlled, phase III study of nonsteroidal aromatase inhibitors (anastrozole or letrozole) plus LY2835219, a CDK4/6 inhibitor, or placebo in postmenopausal women with hormone receptor-positive, HER2-negative locoregionally recurrent or metastatic breast cancer with no prior systemic therapy in this disease setting.

Breast - Metastatic, BRCA 1 and BRCA 2

Brocade 3 (M12-914)

A Phase 3 randomized placebo-controlled trial of carboplatin and paclitaxel with or without veliparib (ABT-888) in HER2-negative metastatirc or locally advanced unresectable BRCA-associated breast cancer.

Breast - Operable, HER2 (+)

Kaitlin (BO24807)

A randomized, multicenter, open-label, phase III trial comparing trastuzumab plus pertuzumab plus a taxane following anthracyclines versus trastuzumab emtansine plus pertuzumab following anthracyclines as adjuvant therapy in patients with operable HER2-positive primary breast cancer.

Breast Registry

Nipple Sparing

ASBrS Nipple Sparing Mastectomy Registry.

Breast – Advanced ER (+) HER2 (-)


A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Fulvestrant with or without Abemaciclib, a CDK4/6 Inhibitor, for Women with Hormone Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer.

Breast, Triple-Negative

LOTUS (GO29277)

A randomized, phase II, multicenter placebo-controlled study of ipatasertib (GDC-0068), an inhibitor of AKT, in combination with paclitaxel as front-line treatment for patients with metastatic triple-negative breast cancer.

Gastric – Metastatic


A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Capecitabine and Cisplatin with or without Ramucirumab as First-line Therapy in Patients with Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma. 

Genetic Registry

City of Hope Registry

Molecular Genetics Studies of Cancer Patients and Their Relatives

Head and Neck – Recurrent or Metastatic

HAWK (D4193C00001)


A Phase II, Multi-Center, Single-Arm, Global Study of MEDI4736 Monotherapy in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN).

Lung - Metastatic


Randomized, double blind, multicenter, phase III study comparing veliparib (ABT-888) plus carboplatin and paclitaxel versus placebo plus carboplatin and paclitaxel in previously untreated advanced or metastatic squamous non-small cell lung cancer (NSCLC).

Lung – Early Stage



A Phase III, Open-Label, Randomized Study to Investigate the Efficacy and Safety of Atezolizumab (ANTI−PD-L1 Antibody) Compared with best Supportive Care Following Adjuvant Cisplatin-Based Chemotherapy in PD-L1−Selected Patients with Completely Resected Stage Ib−IIIa Non−Small Cell Lung Cancer.

Lung – Metastatic


A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti−Pd-L1 Antibody) in Combination with Carboplatin + Paclitaxel with or without Bevacizumab Compared with Carboplatin + Paclitaxel + Bevacizumab in Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non−Small Cell Lung Cancer.

Lung – NSCLC (Treatment Experienced)

JAVELIN (EMR 100070-004)

A Phase III Open-Label, Multicenter Trial of Avelumab (MSB0010718C) Versus Docetaxel in Subjects with Non-Small Cell Lung Cancer that has Progressed After a Platinum-Containing Doublet.

Multiple Myeloma

MAIA (54767414MMY3008)


A Phase 3 Study Comparing Daratumumab, Lenalidomide, and Dexamethasone (DRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects with Previously Untreated Multiple Myeloma who are Ineligible for High Dose Therapy.

Myelodysplastic Syndromes (MDS) / Acute Myeloid Leukemia (AML)

Connect® MDS and AML Registry

Connect® MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry.


Three Women Photo

Cancer risk assessment, screening and prevention programs are vital to educating people about reducing their chances of developing cancer and assessing the need for intervention. Under the direction of our genetic nurse counselor and the Bienes Cancer Center physicians, our Cancer Risk and Prevention Program is for anyone with cancer or a family history of cancer. The vast majority of participants are women who have or have had breast or ovarian cancer, or are at high risk of developing these two cancers. Click to learn more about Genetic Counseling.

Cancer Resources

More Cancer Resources

®2005-2011 WebMD, LLC. All rights reserved.

WebMD does not provide medical advice, diagnosis or treatment.

See additional information.


image description